Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
monarchE: abemaciclib plus adjuvant endocrine therapy versus adjuvant endocrine therapy alone in high-risk HR-positive, HER2-negative early breast cancer
MOH_2017-05-07_000381Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Started May 2017; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-05-07_000381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-07_000381.